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https://doi.org/10.1016/j.ccell.2018.03.018SUMMARYCombination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predic-
tors of response to combination therapy are unknown. Using whole-exome sequencing to examine non-
small-cell lung cancer (NSCLC) treated with PD-1 plus CTLA-4 blockade, we found that high tumor mutation
burden (TMB) predicted improved objective response, durable benefit, and progression-free survival. TMB
was independent of PD-L1 expression and the strongest feature associated with efficacy in multivariable
analysis. The low response rate in TMB low NSCLCs demonstrates that combination immunotherapy does
not overcome the negative predictive impact of low TMB. This study demonstrates the association between
TMB and benefit to combination immunotherapy in NSCLC. TMB should be incorporated in future trials
examining PD-(L)1 with CTLA-4 blockade in NSCLC.INTRODUCTION
T cell checkpoint inhibitors have improved the survival of patients
with a multitude of advanced malignancies. Antibodies targetingSignificance
Our study examines the molecular features associated with res
of PD-1 plus CTLA-4 blockade. Contrary to our initial hypothesi
with benefit. Combination immunotherapy may be particularly
come the negative predictive impact of lowmutation burden. Th
burden as a predictive marker and provides insight into the det
mune checkpoint blockade therapy.
Cancer Cell 33, 843–852, May 14,
This is an open access article undprogrammed cell death receptor-1 (PD-1) or its ligand (PD-L1)
are now approved for treating multiple cancers, including non-
small-cell lung cancer (NSCLC) (Borghaei et al., 2015; Reck
et al., 2016). Responses to anti-PD-(L)1 monotherapies have theponse in patients with NSCLC treated with the combination
s, tumormutation burden is the strongest feature associated
effective in those with high TMB but is insufficient to over-
is report highlights the critical importance of tumormutation
erminants of response in those treated with combination im-
2018 ª 2018 Francis Crick Institute. Published by Elsevier Inc. 843
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1. Baseline Clinical Characteristics
Patient Characteristics
(n = 75)
All Patients TMB Low TMB High
p ValueNo. (%) No. (%) No. (%)
Age (years), median
(range)
66 (42–87) 66 (43–85) 65 (42–87) 0.7739
Gender
Male 37 (49) 17 (45) 20 (54) 0.4916
Female 38 (51) 21 (55) 17 (46)
Histology
Non-squamous 59 (79) 31 (82) 28 (76) 0.5829
Squamous 16 (21) 7 (18) 9 (24)
Smoking status
Current/former 60 (80) 24 (63) 36 (97) 0.0003
Never 15 (20) 14 (37) 1 (3)
Stage
IIIB 9 (12) 6 (16) 3 (8) 0.4799
IV 66 (88) 32 (84) 34 (92)
Performance status
ECOG 0 30 (40) 16 (42) 14 (38) 0.8147
ECOG 1 45 (60) 22 (58) 23 (62)
PD-L1 expression
0% 25 (33) 13 (34) 12 (32) 0.8037a
R1% 45 (60) 21 (55) 24 (65)




24 (32) 5 (13) 19 (51) 0.0018
Stable disease 27 (36) 17 (45) 10 (27)
Progression/not
evaluable




37 (49) 13 (34) 24 (65) 0.0111
No durable benefit
(NDB)
38 (51) 25 (66) 13 (35)
p values in bold type represent significance <0.05. See also Figure S1 and
Tables S1 and S2.
aReflects comparison of PD-L1 0% versusR1%.potential for remarkable durability, but occur in only a minority of
patients. This experience highlights two primary opportunities
for continued progress: identification of predictive biomarkers of
response and development of combinatorial treatment ap-
proaches that improve the frequency, depth, and duration of
response.
Toward identification of predictors of response to anti-PD-(L)1
monotherapy, tumor expression of PD-L1 has been a primary
focus. However, the sensitivity and specificity of PD-L1 expres-
sion is modest (Reck et al., 2016; Taube et al., 2014), which has
prompted the search for additional predictive tools. Our group
and others have identified an association between increased
nonsynonymous tumor mutation burden (TMB) and response
in patients with melanoma treated with CTLA-4 blockade
(Snyder et al., 2014; Van Allen et al., 2015), NSCLCs treated
with PD-1 blockade (Carbone et al., 2017; Rizvi et al., 2015; Rizvi844 Cancer Cell 33, 843–852, May 14, 2018et al., 2018), mismatch repair deficient tumors treated with PD-1
blockade (Le et al., 2017), and bladder cancers treated with PD-
L1 blockade (Rosenberg et al., 2016).
In parallel to these correlative efforts, multiple ongoing clinical
trials are attempting to improve response rates by combining im-
munotherapies. Pre-clinical (Wei et al., 2017) and clinical (Ham-
mers et al., 2017; Hellmann et al., 2017; Wolchok et al., 2017)
studies have identified non-redundant effects of CTLA-4 and
PD-1 signaling and synergistic anti-tumor responses (Curran
et al., 2010). To date, the genomic determinants of response to
combination immunotherapy have not been defined.
We sought to examine the molecular features correlated with
response in patients with NSCLC treated with combination
immunotherapy. In particular, we focused on whether TMB
would correlate with response, as it has in patients treated with
PD-1 monotherapy, or if combination therapy may broaden the
repertoire of effective anti-tumor immunity and thereby diminish
the importance of TMB.
RESULTS
Genomic and Clinical Characteristics of Study Cohort
Are Generalizable
We performed whole-exome sequencing (WES) on tumor tissue
and paired blood (Van Allen et al., 2014) collected from 75 pa-
tients with NSCLC treated with nivolumab plus ipilimumab as
part of the CheckMate-012 study (Hellmann et al., 2017)
(Table 1). The clinical features and efficacy outcomes in the
cohort of patients examined with WES were similar to the overall
set of patients enrolled in CheckMate-012 (Figure S1; Tables S1
and S2). Themean target coverage was 148X (interquartile range
[IQR] 116-182X) in tumors and 81X (IQR 70-98X) in normal; 94%
of target sequences were sequenced to at least 20X depth in tu-
mors (Table S3). Sequencing coverage was similar between re-
sponders and non-responders (Figure S2A). TMB was defined
as total number of nonsynonymous single nucleotide and indel
variants (Table S3). Except for expected differences by smoking
status, baseline clinical variables were similar between those
with TMB above versus below median (Table 1).
The median and distribution of TMB and transition/transver-
sion ratio in this study were similar to NSCLC tumors sequenced
as part of The Cancer Genome Atlas (TCGA) (Campbell et al.,
2016) (Figure S2B and Table S3).
Tumor Mutation Burden Is Significantly Associated with
Improved Efficacy of Combination Immunotherapy
TMBwas higher in patients with objective response (complete or
partial response) compared with those with no response (stable
or progressive disease) (median TMB 273 versus 114 mutations,
Mann-Whitney p = 0.0004, Figure 1A). Similar results were seen
when comparing patients with durable clinical benefit (DCB; par-
tial or stable response for >6 months) with those with no durable
benefit (NDB) (median TMB 210 versus 113, Mann-Whitney p =
0.0071). Objective response rate, DCB rate, and progression-
free survival (PFS) were all greater in patients with high TMB
(>median, 158 mutations) compared with low TMB (%median)
(overall response rate [ORR] 51% versus 13%, Fisher’s exact
p = 0.0005; DCB 65% versus 34%, Fisher’s exact p = 0.011;




Figure 1. TMB Correlates with Efficacy in Patients with NSCLC Treated with Nivolumab Plus Ipilimumab
(A) TMB in patients with complete response (CR)/partial response (PR) (n = 24, blue) versus stable disease (SD)/progressive disease (PD) (n = 51, red) (median 273
versus 114 mutations, Mann-Whitney p = 0.0004) and TMB in patients with DCB (green, n = 37) versus those with NDB (purple, n = 38) (median 210 versus 113
mutations, Mann-Whitney p = 0.0071). Medians, interquartile ranges, and minimum/maximum shown in boxplots.
(legend continued on next page)
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1C). There was a strong association between increased TMB
and increased rate of ORR or DCB (ORR area under the curve
[AUC] 0.75, p = 0.0006, DCB AUC 0.68, p = 0.0076) (Figure 1D).
To contextualize this dataset and facilitate generalizability, we
also characterized TMB in this cohort as a percentile rank of
NSCLCsprofiledbyTCGA.Serial increases inpercentile threshold
were associated with improved PFS (Figure 1E). Patients with tu-
mors in either the upper half or upper tertile of TMB had signifi-
cantly improved ORR and PFS (Figures S2C and S2D).
Computationally Predicted Neoantigen Burden
and Mutation Burden Are Closely Correlated
Consistent with previous reports (Rizvi et al., 2015) and potentially
indicative of the mechanistic importance of neoantigens gener-
ated from somatic nonsynonymous mutations (Schumacher and
Schreiber, 2015), TMB (defined as nonsynonymous variants)
was more strongly associated with ORR and PFS than mutation
burden inclusive of silent variants (Figure S2E). However, compu-
tationally predicted candidate neoantigen burden (Nathanson
et al., 2017) (Table S3) was not more predictive than TMB of
clinical benefit when using either a moderate or strong threshold
(500 nM or 50 nM) of neoantigen binding affinity to patient-spe-
cific class I HLA alleles (Figure S2F). Clonal predicted neoantigen
burdenwasmore predictive of improvedPFS comparedwith total
predicted neoantigen burden (> versus % median predicted
clonal neoantigens, log rank p = 0.04; > versus % median
total predicted neoantigens versus p = 0.07). TMB and computa-
tionally predicted neoantigen burden were highly correlated
(Spearman r 0.92, p < 0.0001; Figure S2G), consistent with this
characteristically proportional relationship (Rooney et al., 2015;
Van Allen et al., 2015). There were no clear associations between
specific HLA alleles and objective response (Figure S2H).
Individual Genes and Additional Molecular Features
Associated with Response or Resistance to
Combination Immunotherapy
We next explored other molecular features that may refine the
association of TMB with response to combination immuno-
therapy (Figure 2). Pre-clinical (Burr et al., 2017; Manguso
et al., 2017; Mezzadra et al., 2017; Patel et al., 2017; Skoulidis
et al., 2015) and clinical reports (Gao et al., 2016; George
et al., 2017; Zaretsky et al., 2016) have described associations
between individual altered genes and response or resistance
to immune checkpoint blockade (Table S4). Relatively few of
these genes were found in this dataset (Figure 2), but some
genes were exclusively associated with resistance in our series,
such as STK11 (zero responses in seven patients with STK11
mutations) and PTEN (0 of 4), consistent with previous reports,
although not reaching statistical significance likely owing to
small numbers (Table S4). IFNGR1 mutations (n = 3) were found(B) Objective response and durable clinical benefit in patients with high TMB (>me
ratio 6.97 [95% confidence interval (CI) 2.19–19.0], Fisher’s exact p = 0.0005; DCB
Proportion of CR/PR or DCB, respectively, are colored on histograms with rate (
(C) PFS in patients with high TMB versus low TMB (median 17.1 versus 3.7 month
(D) Receiver operating characteristic (ROC) curves for correlation of TMB with ob
and DCB (green line) (AUC 0.68 [95% CI 0.56–0.8], p = 0.0076).
(E) PFS in cohorts of patients defined by quartiles of TMB percentile rank among
See also Figure S2 and Table S3.
846 Cancer Cell 33, 843–852, May 14, 2018only in responders. To identify other potential genes of interest,
we identified significantly recurrent genes usingMutSigCV (Law-
rence et al., 2013) (Table S4). Of these genes, only TP53 muta-
tions were enriched in responders (odds ratio 2.9, Fisher’s exact
p = 0.048, Figures S3A and S3B). Notably, TP53mutations were
also associated with increased mutation burden in both the
cohort of combination immunotherapy NSCLCs and TCGA
NSCLCs (Figures S3C–S3F and Table S4).
Additionally, to explore the applicability of targeted next-gen-
eration sequencing as an estimate of exonic mutation burden
(Chalmers et al., 2017; Zehir et al., 2017), we found that limiting
variants to the 468 genes represented in our institutional MSK-
IMPACT panel (Zehir et al., 2017) or the 315 genes in the
FoundationOne panel (Frampton et al., 2013) maintained similar
predictive fidelity for efficacy (Figures S3G–S3H).
Tumor Mutation Burden Is Independent of PD-L1
and Remains Significantly Associated with Efficacy in
Multivariable Analysis
Lastly, we examined the impact of mutation burden on response
in the context of tumor PD-L1 expression, which was known in
70 of 75 patients (93%). There was no correlation between
PD-L1 expression and TMB (Spearman r 0.087, p = 0.48; Fig-
ure 3A). The distribution of TMB was similar in those with PD-L1
positive versus PD-L1 negative tumors (median 162 versus 135,
Mann-Whitney p = 0.89). In multivariable analysis incorporating
PD-L1 expression, histology, smoking status, performance sta-
tus, and tumor burden, TMB was independently associated
with ORR (p = 0.001, Figure 3B) and PFS (p = 0.002, Figures
3C and S4A). When considered in composite, patients with pos-
itive PD-L1 expression (defined as R1% expression) and high
TMB (defined as > median) had significantly improved rates of
ORR and PFS compared with those tumors with only one or
neither variable (ORR chi-square for trend p < 0.0001, Figure 3D;
PFS log rank for trend p = 0.0072, Figure S4B). Of particular note,
four of five responders whose tumors were PD-L1 negative had
high mutation burden (absolute mutation burden range 307–
1175, TCGA percentile rank 72-98th-tile), including one with a
pathologically confirmed complete response (Figure S4C).
DISCUSSION
In patients with advanced cancers treated with PD-1 blockade
monotherapy, multiple reports across multiple tumor types
(Carbone et al., 2017; Le et al., 2017; Rizvi et al., 2015; Rosen-
berg et al., 2016; Snyder et al., 2014; Van Allen et al., 2015)
have identified an association between increased TMB and
increased likelihood of disease control. However, prior to this
report, the significance of TMB for predicting response to com-
bination immunotherapy in NSCLC was not known. In fact, wedian, 158 mutations) versus low TMB (%median) (ORR 51% versus 13%, odds
65% versus 34%, odds ratio 3.55 [95%CI 1.3–8.64], Fisher’s exact p = 0.011).
n/N) shown above each bar.
s, Mantel-Haenszel hazard ratio 0.41 [95% CI 0.23–0.73], log rank p = 0.0024).
jective response (CR/PR; blue line) (AUC 0.75 [95% CI 0.62–0.88], p = 0.0006)
NSCLC tumors profiled by TCGA (log rank for trend p = 0.01).
Figure 2. Summary of Clinical and Molecular Features Associated with Response or Non-response in Patients with NSCLC Treated with
Nivolumab Plus Ipilimumab
Individual patients are represented in each column, organized by those with objective response on the left (blue) and those with no objective response on the right
(red). Categories of histology (squamous or non-squamous) and smoking status (never or ever) are characterized. PD-L1 expression is stratified as 0%, 1%–49%,
orR50%. PFS is shown in months, with the color of each bar representing those who are censored (dark blue) or have progressed (light blue). The NSCLC TCGA
percentile rank for each case is described from 0% to 100% in light to dark purple. Nonsynonymous TMB andmutation burden quantified using genes including in
theMSK-IMPACT targeted next-generation sequencing panel are shown in histograms. The percent of transitions (light green) and transversions (dark green) are
shown. Candidate neoantigen burden is quantified in histograms, stratified by predicted patient-specific HLA binding affinity 0–50 nM (orange) or 50–500 nM (light
yellow). The occurrences of selected genes in each case are represented in the oncoprint, with the percent frequency in responders or non-responders shown.
See also Figures S2 and S3; Tables S3 and S4.initially hypothesized that TMB in patients with NSCLCs would
not impact response to PD-1 plus CTLA-4 blockade therapy. In
an analogous scenario, the impact of PD-L1 expression is
abated in patients with melanoma treated with PD-1 plus
CTLA-4 blockade (Wolchok et al., 2017), and in a report of 17 pa-
tients with melanoma treated with combination immunotherapy,
TMB did not correlate with response (Goodman et al., 2017). In
contrast, we found that TMB is the strongest predictor of efficacy
identified in our dataset of patients with NSCLC. Similar results
were seen in a recent report of patients with small cell lung can-
cer treated with PD-1 plus CTLA-4 blockade (Hellmann et al.,
2018), suggesting the importance of TMB as biomarker for com-
bination immunotherapy across lung cancers.
Given the correlation between TMB and efficacy, it is tanta-
lizing to consider how TMB may be applied prospectively as a
biomarker. One criticism of determining TMB by WES, as we
have in this study, is that WES is currently challenging to performin an expeditious time frame and at adequate scale needed for
general use in patients with advanced NSCLC. Emerging inde-
pendent sets of data have demonstrated that targeted next-gen-
eration sequencing (NGS) panels, which are already being used
routinely in clinic, may provide a reasonable estimate of exonic
mutation burden (Chalmers et al., 2017; Rizvi et al., 2018; Zehir
et al., 2017). We found that estimated TMB using only genes
covered in US Food and Drug Administration-approved targeted
NGS panels MSK-IMPACT (Zehir et al., 2017) and Foundatio-
nOne (Frampton et al., 2013) were similarly predictive to the
TMB derived from WES. These currently available assays may
provide a practical platform for clinical practice now. Further-
more, although the technology is still being optimized, use of
cell-free DNA in plasma to estimate TMB has recently been
shown to be feasible and, when detectable, to correlate with
TMB estimated from tumor tissue (Fabrizio et al., 2017; Gandara
et al., 2017).Cancer Cell 33, 843–852, May 14, 2018 847
BC
D
A Figure 3. Association between TMB and Efficacy in Multivariate
Context
(A) Correlation between TMB and PD-L1 expression (Spearman r 0.087
[95% CI 0.32 to 0.16], p = 0.48). Patients with CR/PR (n = 24) are colored in
blue circles; those with SD/PD (n = 51) are colored in gray squares.
(B) ROC curves for multivariate model correlation with objective response (CR/
PR), with model including TMB (continuous variable), PD-L1 (continuous),
histology (binary, squamous versus non-squamous), smoking status (binary,
ever versus never), performance status (Eastern Cooperative Oncology Group
[ECOG] 0 versus 1), and tumor burden (binary, > versus%median) (plain line,
AUC 0.869). Univariate correlation of TMB with objective response is shown
again for reference (dotted line).
(C) ROC curves for univariate correlation of TMB (continuous) with progres-
sion-free survival (dotted line) at 6 months (purple, AUC = 0.585) or 12 months
(yellow, AUC = 0.558). ROC curves for multivariate correlation of model
including TMB (continuous), PD-L1 (continuous), histology (squamous versus
non-squamous), smoking status (ever versus never), performance status
(ECOG 0 versus 1), and tumor burden (binary, > versus%median) also shown
(plain lines; at 6 months AUC = 0.764, at 12 months AUC = 0.831).
(D) Histogram of objective response (CR/PR) to nivolumab plus ipilimumab in
patients characterized by high mutation burden (>median TMB) and PD-L1
expression (R1%), high mutation burden or PD-L1 expression, or neither.
Response rates (n/N) are shown above each bar, with proportion of those with
PR/CR colored in blue. Chi-square for trend p < 0.0001.
See also Figure S4.
848 Cancer Cell 33, 843–852, May 14, 2018The mechanism(s) underlying the association between TMB
and benefit with immunotherapy is not entirely clear. A leading hy-
pothesis suggests that neoantigens, tumor-specific non-self pep-
tides resulting from somatic nonsynonymous mutations, repre-
sent the mechanistic link. Several pre-clinical and clinical reports
have described neoantigen-specific T cell responses that direct
anti-tumor immunity (Gubin et al., 2014; Hadrup et al., 2009;
McGranahan et al., 2016; Tran et al., 2015; van Rooij et al.,
2013). Neoantigen-specific T cell responses appear to be few in
numbers for any given patient, such that increased TMB may
associate with increased benefit by increasing the chance for an
effective neoantigen to be generated and presented. The
decreased predictive strength of total, rather than nonsynony-
mous, TMBonefficacy found inour studysupports thishypothesis
by emphasizing the particular importance of nonsynonymous var-
iants. However, the capacity to computationally predict neoanti-
gens from exome sequences remains incomplete. In this study,
similar toothers, predicted neoantigenburdenwas largelypropor-
tional to mutation burden and did not appear to have distinct pre-
dictive power. In one study (Van Allen et al., 2015), shuffling of
HLAs such that neoantigen predictions were no longer based on
patient-specific HLA alleles had no impact on the association of
neoantigen burden and benefit. These data suggest that current
routine neoantigen prediction algorithms based on predicted
peptide-HLA binding affinity alone are inadequate. Future work
to incorporatemorenuancedunderstandingof neoantigenclonal-
ity (McGranahan et al., 2016), fitness (Luksza et al., 2017), and
interactions with T cell receptor binding (Glanville et al., 2017)
are critical, especially aspersonalized vaccine strategies targeting
tumor-specific predicted neoantigens are now under way in the
clinic (Ott et al., 2017; Sahin et al., 2017).
Although TMB was the strongest feature associated with effi-
cacy in this study, it remains an unrefined metric. Further refine-
ment in understanding the molecular determinants of response
to immunotherapy will likely come from identification of
key somatic variants that mediate response or resistance to
immunotherapy. Recent case reports of acquired resistance (An-
agnostou et al., 2017; Zaretsky et al., 2016) and pre-clinical
reports usingCRISPR/Cas9 screening (Burr et al., 2017;Manguso
et al., 2017; Patel et al., 2017) have begun to elucidate genes in
both tumors and T cells that are critical to response or resistance
to immunotherapy.However,mutations in eachof these individual
genes appear to be relatively uncommon at least in pre-treatment
tissue; selective pressure from immunotherapy at acquired resis-
tance may reveal a distinct genomic landscape. Among recurrent
genes inourcohort,TP53wasmodestlyassociatedwith increased
response but evenmore strongly associatedwith increased TMB.
The association betweenTP53alterations andTMBwasalso seen
in a recent report of TCGA lung adenocarcinomadata (Dong et al.,
2017), and is perhaps expected given the function of TP53 (Levine
and Oren, 2009) and its known association with smoking (Pfeifer
et al., 2002). STK11 was exclusively associated with resistance,
which aligns with previous reports describing the T cell excluded
phenotype associated with these variants (Skoulidis et al., 2015),
but did not reach statistical significance. Studies of larger size
will ultimately be critical to define the landscape and frequency
of ‘‘immunologic drivers’’ in NSCLC and other cancers.
In addition to refining the genomic features that associate with
response and resistance to immune checkpoint blockade, a com-
bination of assaysmaybehelpful to predict outcomeswith greater
sensitivity and specificity. Here, similar to patients with NSCLC
treated with PD-1 monotherapy, we found that efficacy was
enhanced in those characterized by both high TMB and PD-L1
positivity. Considering both variables together begins to explain
patients who may otherwise be considered curious exceptions
(e.g., PD-L1 negative responders who have high TMB) and further
improves predictive accuracy using the composite of TMB and
PD-L1. The incorporation of assays, such as peripheral T cell phe-
notyping, Tcell receptorsequencing,multiplexpathology imaging,
bulk and single-cell gene expression profiling, may provide addi-
tional biological insight and clinical predictive power in the future.
We did not identify distinct molecular features of response to
combination immunotherapy relative to what has been
described in patients with NSCLC treated with PD-1 blockade
monotherapy. It remains uncertain how PD-1 plus CTLA-4
blockade may improve response rates compared with PD-1
blockade monotherapy. Given the magnitude of benefit in pa-
tients with TMB high tumors, we speculate that response among
patients with TMB high tumors is further improvedwith combina-
tion therapy and/or there is a modest heightening of the slope
associating TMB and benefit relative to PD-1 blockade mono-
therapy. Important questions remain about the mechanisms of
underlying benefit of combination CTLA-4 plus PD-1 blockade
and how these therapies synergize in the context of high TMB.
In our report, the persistently low response rate in patients who
were TMB low/PD-L1 negative demonstrates that combination
therapy does not overcome the barriers to response in those pa-
tients who are least likely to respond to PD-1 blockade.
Other limitations of this study include its retrospective nature,
such that tissue was not available for all patients treated on this
clinical trial and there was insufficient tissue to perform addi-
tional expression analysis. Importantly, however, the clinical
characteristics and outcomes in the cohort analyzed here were
similar to the overall group of patients treated with nivolumab
plus ipilimumab on CheckMate-012.In summary, we demonstrate that TMB strongly predicted
efficacy in patients with NSCLC treated with combination PD-1
plus CTLA-4 blockade. TMB is independent of other clinicopath-
ologic features, including PD-L1 expression. Based in part on
these data, an assessment of TMB has been incorporated in a
Phase III trial examining the benefit of PD-1 plus CTLA-4
blockade (CheckMate227).
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MutSigCV Lawrence et al., 2013 (PMID 23770567); http://software.broadinstitute.org/cancer/
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MutSigCV
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R 3.3.2 R software https://www.r-project.org/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Matthew Hellmann
(hellmanm@mskcc.org).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Combination Immunotherapy Treated Patients
All patients had stage IV non-small cell lung cancer (NSCLC) and were treated on CheckMate 012 (NCT01454102 (Hellmann et al.,
2017)) (Table S1 and Table S2). All patients initiated therapy between February 2013 and March 2015 and were treated with a com-
bination of nivolumab and ipilimumab. All patients consented to an Institutional ReviewBoard-approved study protocol for treatment,
tissue collection, and biomarker analysis at institutions that participated in CheckMate 012 (Memorial Sloan Kettering Cancer Center,
H Lee Moffitt Cancer Center, Fox Chase Cancer Center, UCLA, Jonsson Comprehensive Cancer Center, Jonsson Comprehensive
Cancer Center, Yale Comprehensive Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Duke Univer-
sity Medical Center, UT Southwestern Medical Center, University of Washington, Juravinski Cancer Centre, McMaster University,
Princess Margaret Cancer Centre, University of Toronto, Ottawa Hospital Cancer Centre, University of Ottawa). PD-L1 expression
was assessed by immunohistochemistry using a previously validated rabbit anti-human anti-PD-L1 monoclonal antibody (clone
28-8; Epitomics, Berlingame, CA, USA). Quantification of tumor membranous PD-L1 expression was performed centrally on pre-
treatment tumor tissue submitted as part of the clinical trial using an analytically validated automated assay developed by Dako
(Carpinteria, CA, USA). A minimum of 100 evaluable tumor cells were required for determination of PD-L1 expression. PD-L1 scoring
was available in 70 of 75 patients; five had unknown expression.
Clinical Efficacy Analyses
Per protocol, tumor assessments were collected at week 10, week 17, week 23, and then every 12weeks until progression. Objective
response was assessed by investigator-assessed RECIST v1.1 (Eisenhauer et al., 2009). Partial and complete responses were
confirmed by repeat imaging occurring at least 4 weeks after the initial identification of response; unconfirmed partial responses
were considered stable disease. Patients with confirmed complete or partial response were considered responders; patients with
stable disease, progressive disease, or not evaluable were considered non-responders.
We also used a related outcomemetric, durable clinical benefit (DCB), which we have previously described (Rizvi et al., 2015; Rizvi
et al., 2018). DCB was defined as stable disease or partial response lasting longer than 6 months; all other patients were considered
to have no durable benefit (NDB).
Progression-free survival was assessed as previously described (Hellmann et al., 2017), with outcomes determined as of the
September 2016 database lock.
Tumor and Germline Samples
All tumor tissue used for sequencing was obtained prior to dosing with combination immunotherapy, with the exception of one non-
responder whose tissue was collected 122 days after beginning therapy (ID# 4). The presence of tumor tissue in the sequenced sam-
ples was confirmed by examination of a representative hematoxylin and eosin-stained slide by thoracic pathologist (N.R.) or central
pathology vendor through Mosaic Labs. Germline DNA was obtained from peripheral blood mononuclear cells from all patients.
METHOD DETAILS
Whole Exome Capture and Sequencing
Whole exome capture libraries were constructed using the Agilent Sure-Select HumanAll Exon v2.0 (44Mb), v4.0 (51Mb), or Illumina’s
Rapid Capture Exome (38Mb) baited target kit. Enriched exome libraries were sequenced on a HiSeq 2000, 2500, or 4000 platform
(Illumina, San Diego, California) to generate paired-end reads (2x76bp) to a goal of 150X mean target coverage (n=70 sequenced at
the Broad Institute, Cambridge, MA; n=5 sequenced at Memorial Sloan Kettering Cancer Center Genomic Core, New York, NY).e2 Cancer Cell 33, 843–852.e1–e4, May 14, 2018
Exome Alignment and Assembly
For each case, a BAM file was produced by aligning tumor and normal sequences to the hg19 human genome build using the Bur-
rows-Wheeler Aligner (BWA) version 0.5.9-tpx (Li and Durbin, 2009). Further indel realignment, base-quality score recalibration, and
duplicate-read removal were performed using the Genome Analysis Toolkit (GATK) version nightly-2015-07-31-g3c929b0 (DePristo
et al., 2011).
Sequencing Quality Control
Quality control metrics were computed using the Broad Institute Picard software. Fingerprint genotypes were used to verify match of
tumor and normal samples. Potential contamination was estimated using ContEst (Cibulskis et al., 2011). Artifacts produced by
oxidation during DNA sequencing were removed using the OxoG3 filter (Costello et al., 2013). Samples with mean target coverage
<60X in tumor or <30X in normal were excluded (Table S3).
Variant Calling
MuTect version v1.1.6 (Cibulskis et al., 2013) was used to generate single nucleotide variant (SNV) calls using default parameters.
Indelocator (http://archive.broadinstitute.org/cancer/cga/indelocator) was used to generate indel calls. Mutations with variant allelic
fraction < 0.05 in tumor were excluded (Taylor-Weiner et al., 2016). Site based artifact filtering was applied to mutations with variant
alleles that were present in an independent panel of normal exomes derived from blood samples of non-cancer patients. Variants
were annotated by Varcode (v. 0.5.15, https://github.com/hammerlab/varcode) and PyEnsembl (v. 1.0.3, https://github.com/
hammerlab/pyensembl) using Ensembl Release 75.
Mutation Burden Quantification
Tumor mutation burden (TMB) was defined as the number of nonsynonymous alterations (SNVs or indels) for each patient (Table S3).
Mutation Burden Percentile Rank Compared to NSCLC Tumors Sequenced by TCGA
To compare the overall spectrum of TMB and determine the percentile rank of TMB of patients sequenced in this study relative to the
TMB seen in larger series of NSCLCs, MAF files of called variants were retrieved from tumors analyzed as part of the lung adenocar-
cinoma and lung squamous cell carcinoma by The Cancer Genome Atlas (TCGA) projects (Campbell et al., 2016). Mutations with
VAF < 0.05 were excluded. For TCGA participants with multiple samples, a single sample was chosen. To reflect a typical histologic
distribution of NSCLC, we used all LUAD participants present in the MAF files (n=569) and selected a subset of available LUSC par-
ticipants (n=141 (29%) of 491 participants) to create a set of 710 samples comprised of 80% adenocarcinoma and 20% squamous
cell carcinoma (Table S3). The TMB of samples in this study were then compared to the TMB of the NSCLC TCGA cohort to assign
each sample a percentile rank.
HLA Analysis
Four-digit class I HLA alleles were inferred using OptiType (https://github.com/FRED-2/Optitype) (Snyder et al., 2017; Szolek
et al., 2014).
In Silico Neoantigen Prediction Pipeline
Using Topiary (https://github.com/hammerlab/topiary/) (Nathanson et al., 2017), the mutated DNA sequences were virtually
translated into corresponding mutated peptide sequences. Topiary was used to run NetMHCcons (v. 1.1) (Karosiene et al., 2012)
in order to predict MHC class I binding affinity for all 8 to 11mer peptide sequences containing the mutated amino acid. For variants
longer than a single residue, all 8-11mers downstream of the variant were considered. Candidate neoantigens were those peptides
with binding affinity IC50 of%500nM to one (or more) of the patient-specific HLA alleles (Table S3); strong binding candidate neo-
antigens were considered those with binding affinity IC50 of%50nM.
Predicted Neoantigen Clonality
To determine the cancer cell fraction (CCF) of each mutation, we integrated the variant allele frequency with the local copy number
with purity and ploidy estimates. Each alteration, the variant allele frequency (VAF) depends on the local copy number of the tumor
(CPNmut), the purity (p), the local copy number of the normal sample (CPNnorm) and also the cancer cell fraction (CCF), defined as
the proportion of cancer cells harboring the mutations. The expected VAF, given the CCF, can be calculated as follows: CAF (CCF) =
p*CCF / CPNnorm (1-p) + p*CPNmut.
For a given mutation with ‘a’ alternative reads, and a depth of ‘N’, the probability of a given CCF can be estimated using a binomial
distribution P(CCF) = binom(aIN, VAF(CCF)). CCF values can then be calculated over a uniform grid of 100 CCF values (0.01, 1) and
subsequently normalized to obtain a posterior distribution. To avoid overestimating the number of clonal alterations, we classified
mutations as clonal if there was >0.5 probability that the cancer cell fraction was >0.95 (Landau et al., 2013). Clonality could be
resolved in all but two patients. We restricted clonality estimation to single nucleotide variants, with copy number as assessed by
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Recurrently Altered Genes
MutSigCV (version 1.4,(Lawrence et al., 2013)) was used to identify recurrently altered genes in both the IpiNivo cohort as well as the
NSCLC TCGA cohort (Table S4). Genes with q values <0.1 were considered to be significantly recurrently mutated.
QUANTIFICATION AND STATISTICAL ANALYSES
Differences in TMB between two groups were examined using the non-parametric Mann-Whitney test. Fisher’s exact test was used
to compare proportions between two groups, or chi-square test for three groups. For progression-free survival analysis, the log-rank
test was used to compare Kaplan-Meier survival curves and the Mantel-Haenszel method was used to determine hazard ratios be-
tween groups. Correlations were examined by the Spearman correlationmethod. Receiver operator characteristic (ROC) curves plot-
ting sensitivity and 1-specificity of continuous variables were assessed by generating the area under the curve; p-values were also
reported. An analysis of enrichment in frequency of altered genes of a priori significance (Table S4) were examined using Odds ratio
and Fisher’s exact test. The frequency of recurrently altered genes identified by MutSigCV were compared in responder vs non-
responder groups as well as high TMB vs low TMB groups using odds ratio and Fisher’s exact text. All reported p-values are two
sided. Correlations betweenmutation burden and PD-L1 expression were determined using the Spearman correlation formula.Multi-
variable logistic and Cox regression were conducted to assess the impact of TMB on ORR and PFS, respectively, while adjusting for
other covariates described. Statistical analyses were performed using GraphPad Prism v.6 and R 3.3.2.
DATA AND SOFTWARE AVAILABILITY
Our dataset, for the 43 patients with consent to share these sequencing data, is deposited in the European Variation Archive. The
accession number for the sequencing data is PRJEB24995, https://www.ebi.ac.uk/eva/?eva-study=PRJEB24995.e4 Cancer Cell 33, 843–852.e1–e4, May 14, 2018
